自从多个治疗靶点的鉴定，例如间变性淋巴瘤激酶(ALK)易位，非小细胞肺癌(NSCLC)患者的治疗范式已经改善。为了保证患者生存期长并且生活质量更好的可能性，我们必须在适当的时间确定共识生物标志物并提供最佳治疗方案给患者。我们报告了一例高加索男性患者，年龄在五十岁代，非吸烟者，突出了ALK阳性患者的复杂旅程。这个特殊案例展示了新型ALK靶向治疗的疗效和耐受性，让我们的患者能够保持日常生活而不影响该治疗的有效性。关注ALK阳性患者的现实情况以及这种治疗对患者日常生活的影响，我们可以增加对这种特定病理的认识。©2023. BioMed Central Ltd., Springer Nature的一部分。

Since the identification of multiple therapeutic targets, as is the case of anaplastic lymphoma kinase (ALK) translocation, the paradigm of treating patients with non-small cell lung cancer (NSCLC) has improved. In order to guarantee the possibility of longer survival outcomes with a better quality of life we must invest in the determination, in suitable time, of the consensual biomarkers and in the availability of the best treatments to our patients.We present a case of a caucasian male in his fifth decade of life, non-smoker, who highlights the complex journey of ALK-positive patients. This particular case, demonstrates the efficacy and tolerability of the new ALK target therapies, allowing our patients to maintain their routines without compromising the effectiveness of the therapy.Focusing on the reality of ALK positive patients and the impact that this therapy has on the daily lives of our patients, we can contribute to the awareness of this specific pathology.© 2023. BioMed Central Ltd., part of Springer Nature.